(Q37565645)

21 August 2017

1 reference

title

Pharmacotherapy of triple-negative breast cancer (English)

1 reference

21 August 2017

0 references

1 reference

3

Kadri Altundag

1 reference

21 August 2017

Cagatay Arslan

1

1 reference

PubMed ID

19640211

21 August 2017

Omer Dizdar

series ordinal

2

1 reference

PubMed ID

19640211

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

13

1 reference

21 August 2017

2081-2093

1 reference

Molecular portraits of human breast tumours

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Racial differences in breast cancer survival in women under age 60.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Triple-negative breast cancer: therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Randomized trials in oncology stopped early for benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Genetic epidemiology of BRCA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Basal-like breast cancer and the BRCA1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Research issues affecting preoperative systemic therapy for operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

BRCA1, a potential predictive biomarker in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Platinum-based chemotherapy in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Bevacizumab in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Specific activity of class II histone deacetylases in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

mTOR pathway and mTOR inhibitors as agents for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Autoimmune hemolytic anemia associated with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

The TRAIL apoptotic pathway in cancer onset, progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

Triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903117309

10.1517/14656560903117309

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19640211